MEDIUM confidence: 100% data completeness, but the composite (56) sits in the indecisive 30–70 range — strong-buy and short calls require a more decisive composite. What does confidence mean?
Technical context for active traders — derived from price, the 50/200-day moving averages, the 52-week range, and recent volume. Not part of the QScore.
AI classification of policy/regulatory sensitivity from the company's sector, industry, and business description. Exposure/sensitivity only — not a political opinion, a prediction of government action, or investment advice. As of 2026-07-10.
Fama-French 5-factor (2×3) + Momentum, monthly OLS with Newey-West errors. Bars show signed factor betas; faded bars/figures aren't statistically significant.
Dated events from the market calendar; the “also watch” items are AI-generated observations from QScoring data. Informational only — not investment advice, and dates can change.
| Metric (USD) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $63.4B— | $68.0B+7.3% | $67.7B-0.4% | $69.9B+3.3% | $77.1B+10.2% |
| EPS (dil.) | $7.65— | $6.30-17.6% | $1.81-71.3% | $5.94+228.2% | $4.80-19.2% |
| Free Cash Flow | $12.8B— | $11.4B-11.3% | $14.3B+25.4% | $15.1B+6.0% | $18.1B+19.8% |
| Gross Margin | 26.6% | 27.9%+1.3pp | 25.5%-2.3pp | 27.2%+1.6pp | 36.4%+9.2pp |
| Operating Margin | 13.4% | 9.4%-4.1pp | 3.2%-6.2pp | 8.0%+4.8pp | 6.0%-2.0pp |
| Net Margin | 10.8% | 7.8%-3.0pp | 2.3%-5.4pp | 6.3%+4.0pp | 4.4%-1.9pp |
Absolute figures with year-over-year change. Margins show the level with the change in percentage points (pp). “n/m” = not meaningful (prior ≤ 0); ⚠ marks a large percentage off a small base — read the dollar figure.
Fewer than 3 analysts refreshed a price target in the last month, so no revision can be computed. Prior quarter: $97 avg across 9 analysts.
Buy-rated share 67% → 67% over ~3 months (+0pp).
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Aug 2026 | $2.30 | $2.43 | +5.7% |
| May 2026 | $2.27 | $2.42 | +6.6% |
| Feb 2026 | $2.34 | $2.58 | +10.3% |
| Nov 2025 | $2.31 | $2.34 | +1.3% |
| Aug 2025 | $2.15 | $2.02 | -6.0% |
| Apr 2025 | $2.00 | $1.96 | -2.0% |
| Feb 2025 | $2.11 | $2.08 | -1.4% |
| Oct 2024 | $2.17 | $1.95 | -10.1% |
Net buyback (repurchases less issuance) ÷ market cap, plus trailing dividend yield.
No recent open-market insider transactions.
Short interest, days-to-cover, and institutional-ownership change require a data-plan upgrade (not yet available).
Forward-return IC, quintile spread & hit rate publish on /performance as the tracking panel accrues enough no-look-ahead history.
Working the DCF backward: holding the assumptions below, this is the free-cash-flow growth today's price implies over the next 10 years. It is a read on the price's embedded expectations — not a fair-value or target price.
The price implies FCF growth below the analyst consensus of 2.8%/yr (revenue basis).
Base free cash flow $15.8B (avg FY2023–FY2025; latest year $18.1B) · equity value $62.3B · levered FCF discounted at the cost of equity. Reverse DCF is illustrative, not advice.
The QScore of 56 for MetLife indicates a neutral outlook, driven by strong momentum and relatively low risk, which scores high on 65. However, the stock's growth and profitability metrics, such as -19.7% EPS growth and 13.0% ROE, weigh down the overall score. The long-term and short-term scores are relatively aligned, with the short-term score slightly higher at 59, suggesting a modest near-term edge. MetLife trades at a P/E of 18.5, exhibiting moderate valuation.